Literature DB >> 15747069

Immediate radical resection after local excision of rectal cancer: an oncologic compromise?

Dieter Hahnloser1, Bruce G Wolff, David W Larson, Jennifer Ping, Santhat Nivatvongs.   

Abstract

PURPOSE: Local excision for early-staged rectal cancers is controversial. Preoperative understaging is not uncommon and radical resection after local resection may be needed for a curative treatment. The aim of this study was to determine the frequency and outcome of radical resection (within 30 days) after local excision for rectal adenocarcinoma.
METHODS: All locally excised rectal cancers (curative intent) that required radical surgery within 30 days were reviewed (1980-2000). T2-3N0-1 stage cancers were each matched to three primary radical surgery controls for stage, age (+/- 5 years), gender, date (+/- 1 years), and type (abdominoperineal resection or low anterior resection) of operation. T1N0-1 cancers were compared with stage-matched rectal cancers treated by either primary radical surgery (n = 78) or local excision alone (n = 77).
RESULTS: Fifty-two locally excised rectal adenocarcinomas (29 transanal and 23 polypectomies) were followed by radical surgery (24 abdominoperineal resection and 28 low anterior resection) within 7 (range, 1-29) days. Radical surgery was performed because of a cancerous polyp (n = 42), positive margins (5), lymphovascular invasion (3), and T3-staged cancer (2). Twelve of 52 cancers (23 percent) were found to have nodal involvement and 15 of 52 (29 percent) showed residual cancer in the resected specimen. The T2-3N0-1 stage controls were well matched. No significant difference in tumor location, size, adjuvant therapy, or length of follow-up was noted. Local and distant recurrence occurred in 2 of 4 T2-3N1 tumors and in 2 of 11 T2-3N0 cancers and were comparable to the matched controls, as was survival, with the exception of shorter survival in T3N1 cases, but numbers were too small for a definitive conclusion. Length of follow-up was not different. For T1 cancers, the controls were also comparable regarding patient and tumor demographics and adjuvant therapy. Nodal involvement was 21 percent in T1 study cases and 15 percent in T1 primary radical-surgery controls, with a trend toward location in the lower third of the rectum in both groups (58 percent and 50 percent, respectively). Local recurrence rates were 3 percent in the study group, 5 percent for patients undergoing primary radical surgery, and 8 percent for local excision alone. Distant metastasis (11 percent, 12 percent, and 13 percent, respectively) and overall five-year survival were also not significantly different (78 percent, 89 percent, and 73 percent, respectively).
CONCLUSIONS: Nodal involvement in attempted locally excised rectal cancers is not uncommon. Local excision of rectal tumors followed by radical surgery within 30 days in cancer patients does not compromise outcome compared with primary radical surgery. Even after radical surgery for superficial T1 rectal cancers, recurrence rates are not insignificant. Future improvements in preoperative staging may be helpful in selecting tumors for local excision only.

Entities:  

Mesh:

Year:  2005        PMID: 15747069     DOI: 10.1007/s10350-004-0900-9

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  47 in total

1.  Depth of tumor invasion independently predicts lymph node metastasis in T2 rectal cancer.

Authors:  Pei-Rong Ding; Xin An; Yun Cao; Xiao-Jun Wu; Li-Ren Li; Gong Chen; Zhen-Hai Lu; Yu-Jing Fang; De-Sen Wan; Zhi-Zhong Pan
Journal:  J Gastrointest Surg       Date:  2010-10-05       Impact factor: 3.452

2.  Colorectal Cancer OncoGuia.

Authors:  Paula Manchon Walsh; Josep M Borràs; Tàrsila Ferro; Josep Alfons Espinàs
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

3.  A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial.

Authors:  Julio Garcia-Aguilar; Qian Shi; Charles R Thomas; Emily Chan; Peter Cataldo; Jorge Marcet; David Medich; Alessio Pigazzi; Samuel Oommen; Mitchell C Posner
Journal:  Ann Surg Oncol       Date:  2011-07-14       Impact factor: 5.344

4.  Usefulness of two independent histopathological classifications of tumor regression in patients with rectal cancer submitted to hyperfractionated pre-operative radiotherapy.

Authors:  Lukasz Liszka; Ewa Zielińska-Pajak; Jacek Pajak; Dariusz Gołka; Jacek Starzewski; Zbigniew Lorenc
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

5.  Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Igor Proscurshim; Fábio G Campos; Wladimir Nadalin; Desiderio Kiss; Joaquim Gama-Rodrigues
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

Review 6.  Local Excision and Endoscopic Resections for Early Rectal Cancer.

Authors:  Guilherme Pagin São Julião; Juan Pablo Celentano; Flavia Andrea Alexandre; Bruna Borba Vailati
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

Review 7.  Transanal endoscopic microsurgery for rectal cancer: T1 and beyond? An evidence-based review.

Authors:  Marco E Allaix; Alberto Arezzo; Mario Morino
Journal:  Surg Endosc       Date:  2016-02-22       Impact factor: 4.584

8.  Transanal endoscopic microsurgery after endoscopic resection of malignant rectal polyps: a useful technique for indication to radical treatment.

Authors:  Simone Arolfo; Marco Ettore Allaix; Marco Migliore; Francesca Cravero; Alberto Arezzo; Mario Morino
Journal:  Surg Endosc       Date:  2013-10-30       Impact factor: 4.584

9.  The Role of Transanal Surgery in the Management of T1 Rectal Cancers.

Authors:  Imran Hassan; Paul E Wise; David A Margolin; James W Fleshman
Journal:  J Gastrointest Surg       Date:  2015-06-06       Impact factor: 3.452

10.  Salvage TME following TEM: a possible indication for TaTME.

Authors:  F Letarte; M Raval; A Karimuddin; P T Phang; C J Brown
Journal:  Tech Coloproctol       Date:  2018-05-04       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.